Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$36.16 USD
-0.42 (-1.15%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $36.13 -0.03 (-0.08%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CYTK 36.16 -0.42(-1.15%)
Will CYTK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CYTK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYTK
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?
CYTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
Other News for CYTK
Cytokinetics (CYTK) Downgraded Amid Potential Challenges
Cytokinetics Merits A Speculative Buy Rating
Cytokinetics Inc (CYTK) Announces Upcoming Q2 2025 Financial Results and Conference Call | CYTK ...
Cytokinetics to Announce Second Quarter Results On August 7, 2025 | CYTK Stock News
Insider Sell: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK)